학술논문
A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA -α5 NAM (basmisanil) on intellectual disability associated with Down syndrome
Document Type
Article
Author
Goeldner, C.; Hipp, J.F.; Hernandez, M.-C.; Khwaja, O.; Noeldeke, J.; Pellicer, S.; Squassante, L.; d’Ardhuy, X.L.; Kishnani, P.S.; Skotko, B.G.; Casero, J.L.; Derks, M.; Lennon-Chrimes, S.; Visootsak, J.; Wandel, C.; Fontoura, P.; De La Torre Fornell, R.; Glue, P.; Hoover-Fong, J.; Uhlmann, S.; Malagón Valdez, J.; Marshall, A.; Martinón-Torres, F.; Redondo-Collazo, L.; Rodriguez-Tenreiro, C.; Marquez Chin, V.; Michel Reynoso, A.G.; Mitchell, E.A.; Slykerman, R.F.; Wouldes, T.; Loveday, S.; Moldenhauer, F.; Novell, R.; Ochoa, C.; Rafii, M.S.; Rebillat, A.-S.; Sanlaville, D.; Sarda, P.; Shankar, R.; Pulsifer, M.; Evans, C.L.; Silva, A.M.; McDonough, M.E.; Stanley, M.; McCary, L.M.; Vicari, S.; Wilcox, W.; Zampino, G.; Zuddas, A.
Source
In: Journal of Neurodevelopmental Disorders . (Journal of Neurodevelopmental Disorders, December 2022, 14(1))
Subject
Language
English
ISSN
18661955
18661947
18661947